

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley 24/1988, de 28 de julio, del Mercado de Valores*) Grifols, S.A. ("Grifols") hereby notifies the National Securities Market Commission of the following

RELEVANT EVENT

Grifols announces that it has signed, jointly with Ortho Clinical Diagnostics, a restated and extended contract through 2026 with Abbott for the production of current antigens in addition to five new ones in its manufacturing facility in Emeryville, California.

The new contract, which extends manufacturing services through 2026, has a total value approximating \$700 Million.

The new "state of the art" facility for the manufacture of recombinant antigens utilized in clinical diagnosis and blood screening, dubbed "Project Horizon", is expected to be completed and licensed by the beginning of 2017. Until the new facility is completed and licensed, the antigens will continue to be produced in Grifols' existing manufacturing facility in Emeryville.

Barcelona, 17 July 2015

Raimon Grifols Roura
Vice-Secretary to the Board of Directors